Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of pravastatin on insulin resistance and HbA1c
KCT0000943Phase 4Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pravastatin in type 2 diabetes mellitus (T2DM), prediabetes and dyslipidemia, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Change in insulin resistance and Change in HbA1c level. Planned start Dec 2013; status: not yet recruiting.
02
Drugs
pravastatin
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetesdyslipidemia
Beyond the preview
Go deeper on KCT0000943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000943.